Jolliffe D,. Continuous and robust measures of the overweight epidemic: 1971-2000. Demography 2004; 41: 303-14.
Obesity: preventing and managing the global epidemic. Report of a WHO consultation. World Health Organ Tech Rep Ser 2000; 894 (i-xii): 1-253.
Ng M, Robinson M, Gupta R, Zhou M, Zhu S, Murray CJL,. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 2014; 384: 766-81.
Lavie CJ, Milani RV, Ventura HO,. Obesity and cardiovascular disease: risk factor, paradox, and impact of weight loss. J Am Coll Cardiol 2009; 53: 1925-32.
Hsu C, McCulloch CE, Iribarren C, Darbinian J, Go AS,. Body mass index and risk for end-stage renal disease. Ann Intern Med 2006; 144: 21-8.
Fox CS, Larson MG, Leip EP, Culleton B, Wilson PWF, Levy D,. Predictors of new-onset kidney disease in a community-based population. JAMA 2004; 291: 844-50.
Iseki K, Ikemiya Y, Kinjo K, Inoue T, Iseki C, Takishita S,. Body mass index and the risk of development of end-stage renal disease in a screened cohort. Kidney Int 2004; 65: 1870-6.
Gelber RP, Kurth T, Buring JE, Levey AS, Gaziano JM,. Association between body mass index and CKD in apparently healthy men. Am J Kidney Dis 2005; 46: 871-80.
Spangler JG, Konen JC,. Hypertension, hyperlipidemia, and abdominal obesity and the development of microalbuminuria in patients with non-insulin-dependent diabetes mellitus. J Am Board Fam Pract 1996; 9: 1-6.
Hanley MJ, Abernethy DR, Greenblatt DJ,. Effect of obesity on the pharmacokinetics of drugs in humans. Clin Pharmacokinet 2010; 49: 71-87.
Bouquegneau A, Vidal-Petiot E, Vrtovsnik F, Cavalier E, Delanaye P, Flamant M,. Modification of Diet in Renal Disease versus Chronic Kidney Disease Epidemiology Collaboration equation to estimate glomerular filtration rate in obese patients. Nephrol Dial Transplant. 2013 Nov; 28 Suppl 4: iv122-30.
Lemoine S, Guebre-Egziabher F, Sens F, Juillard L, Dubourg L, Hadj-Aissa A,. Accuracy of GFR estimation in obese patients. Clin J Am Soc Nephrol 2014; 9: 720-7.
KDIGO. CKD Evaluation & Management [online]. Available at http://kdigo.org/home/guidelines/ckd-evaluation-management (last accessed in May 2015).
Delanaye P, Pottel H, Botev R,. Con: should we abandon the use of the MDRD equation in favour of the CKD-EPI equation? Nephrol Dial Transplant 2013; 28: 1396-403.
Froissart M, Rossert J, Jacquot C, Paillard M, Houillier P,. Predictive performance of the modification of diet in renal disease and Cockcroft-Gault equations for estimating renal function. J Am Soc Nephrol JASN 2005; 16: 763-73.
Delanaye P, Mariat C,. The applicability of eGFR equations to different populations. Nat Rev Nephrol 2013; 9: 513-22.
Huang S-M, Temple R, Xiao S, Zhang L, Lesko LJ,. When to conduct a renal impairment study during drug development: US Food and Drug Administration perspective. Clin Pharmacol Ther 2009; 86: 475-9.
EMA. Guideline on the evaluation of the pharmacokinetics of 4 medicinal products in patients with decreased renal 5 function. Available at http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2014/02/WC500162133.pdf (last accessed in May 2015).
Matzke GR, Aronoff GR, Atkinson AJ, Inker LA, Umans JG, Murray P,. Drug dosing consideration in patients with acute and chronic kidney disease-a clinical update from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2011; 80: 1122-37.
FDA. Pharmacokinetics in patients with impaired renal function-study design, data analysis, and impact on dosing and labeling. Available at http://www.fda.gov/downloads/Drugs/Guidances/UCM204959.pdf (last accessed in May 2015).
Delanaye P, Mariat C, Cavalier E, Krzesinski J-M,. Errors induced by indexing glomerular filtration rate for body surface area: reductio ad absurdum. Nephrol Dial Transplant 2009; 24: 3593-6.
Gehan EA, George SL,. Estimation of human body surface area from height and weight. Cancer Chemother Rep 1970; 54: 225-35.
Mosteller RD,. Simplified calculation of body-surface area. N Engl J Med 1987; 317: 1098.
Du Bois D, Du Bois EF,. A formula to estimate the approximate surface area if height and weight be known. Arch Int Med. 1916; 17: 863-71.
Livingston EH, Lee S,. Body surface area prediction in normal-weight and obese patients. Am J Physiol Endocrinol Metab 2001; 281: E586-91.
Delanaye P, Radermecker RP, Rorive M, Depas G, Krzesinski JM,. Indexing glomerular filtration rate for body surface area in obese patients is misleading: concept and example. Nephrol Dial Transplant 2005; 20: 2024-8.
Mazzachi BC, Peake MJ, Ehrhardt V,. Reference range and method comparison studies for enzymatic and Jaffé creatinine assays in plasma and serum and early morning urine. Clin Lab 2000; 46: 53-5.
Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF, Feldman HI,. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009; 150: 604-12.
Levey AS, Coresh J, Greene T, Van Lente F,. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med 2006; 145: 247-54.
Erstad BL,. Dosing of medications in morbidly obese patients in the intensive care unit setting. Intensive Care Med 2004; 30: 18-32.
Pai MP, Paloucek FP,. The origin of the 'ideal' body weight equations. Ann Pharmacother 2000; 34: 1066-9.
Sasson AN, Cherney DZ,. Renal hyperfiltration related to diabetes mellitus and obesity in human disease. World J Diabetes 2012; 3: 1-6.
Cachat F, Combescure C, Cauderay M, Girardin E, Chehade H,. A systematic review of glomerular hyperfiltration assessment and definition in the medical literature. Clin J Am Soc Nephrol 2015; 10: 382-9.
Begg EJ, Chin PKL,. A unified pharmacokinetic approach to individualized drug dosing. Br J Clin Pharmacol 2012; 73: 335-9.
Lalonde RL, Wagner JA,. Drug development perspective on pharmacokinetic studies of new drugs in patients with renal impairment. Clin Pharmacol Ther 2009; 86: 557-61.
Chin PKL, Florkowski CM, Begg EJ,. The performances of the Cockcroft-Gault, Modification of Diet in Renal Disease study and Chronic Kidney Disease Epidemiology Collaboration equations in predicting gentamicin clearance. Ann Clin Biochem 2013; 50: 546-57.
Nyman HA, Dowling TC, Hudson JQ, Peter WLS, Joy MS, Nolin TD,. Comparative evaluation of the Cockcroft-Gault equation and the Modification of Diet in Renal Disease (MDRD) study equation for drug dosing: an opinion of the Nephrology Practice and Research Network of the American College of Clinical Pharmacy. Pharmacotherapy 2011; 31: 1130-44.
Wuerzner G, Bochud M, Giusti V, Burnier M,. Measurement of glomerular filtration rate in obese patients: pitfalls and potential consequences on drug therapy. Obes Facts 2011; 4: 238-43.
Saracino A, Morrone LF, Suriano V, Fanelli M, Rubini G, Coratelli P,. A simple method for correcting overestimated glomerular filtration rate in obese subjects evaluated by the Cockcroft and Gault formula: a comparison with 51Cr EDTA clearance. Clin Nephrol 2004; 62: 97-103.
Dowling TC, Matzke GR, Murphy JE, Burckart GJ,. Evaluation of renal drug dosing: prescribing information and clinical pharmacist approaches. Pharmacotherapy 2010; 30: 776-86.
Pai MP, Nafziger AN, Bertino JS,. Simplified estimation of aminoglycoside pharmacokinetics in underweight and obese adult patients. Antimicrob Agents Chemother 2011; 55: 4006-11.
Dufour B, Toussaint-Hacquard M, Kearney-Schwartz A, Lecompte T, Benetos A, Perret-Guillaume C,. Glomerular filtration rate estimated by Cockcroft-Gault formula better predicts anti-Xa levels than modification of the diet in renal disease equation in older patients with prophylactic enoxaparin. J Nutr Health Aging 2012; 16: 647-52.
Friedman AN, Strother M, Quinney SK, Hall S, Perkins SM, Brizendine EJ,. Measuring the glomerular filtration rate in obese individuals without overt kidney disease. Nephron Clin Pract 2010; 116: c224-34.
Demirovic JA, Pai AB, Pai MP,. Estimation of creatinine clearance in morbidly obese patients. Am J Health Syst Pharm 2009; 66: 642-8.
Verhave JC, Fesler P, Ribstein J, du Cailar G, Mimran A,. Estimation of renal function in subjects with normal serum creatinine levels: influence of age and body mass index. Am J Kidney Dis 2005; 46: 233-41.
Stevens LA, Nolin TD, Richardson MM, Levey AS, Chronic Kidney Disease Epidemiology Collaboration. Comparison of drug dosing recommendations based on measured GFR and kidney function estimating equations. Am J Kidney Dis 2009; 54: 33-42.
Park EJ, Pai MP, Dong T, Crentsil V, Zhang L, Xu NN,. The influence of body size descriptors on the estimation of kidney function in normal weight, overweight, obese, and morbidly obese adults. Ann Pharmacother 2012; 46: 317-28.
Healy MF, Speroni KG, Eugenio KR, Murphy PM,. Adjusting eptifibatide doses for renal impairment: a model of dosing agreement among various methods of estimating creatinine clearance. Ann Pharmacother 2012; 46: 477-83.
Lessard BA, Zaiken K,. Comparison of equations for dosing of medications requiring renal adjustment. J Am Pharm Assoc 2013; 53: 54-7.
Kaag D,. Carboplatin dose calculation in lung cancer patients with low serum creatinine concentrations using CKD-EPI and Cockcroft-Gault with different weight descriptors. Lung Cancer Amst Neth 2013; 79: 54-8.
Dooley MJ, Poole SG, Rischin D,. Dosing of cytotoxic chemotherapy: impact of renal function estimates on dose. Ann Oncol 2013; 24: 2746-52.
Cockcroft DW, Gault MH,. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41.
Chagnac A, Herman M, Zingerman B, Rozen-Zvi B, Hirsh J, Gafter U,. Obesity-induced glomerular hyperfiltration: its involvement in the pathogenesis of tubular sodium reabsorption. Nephrol Dial Transplant 2008; 23: 3946-52.
Green B, Duffull SB,. What is the best size descriptor to use for pharmacokinetic studies in the obese? Br J Clin Pharmacol 2004; 58: 119-33.
Spinler SA, Nawarskas JJ, Boyce EG, Connors JE, Charland SL, Goldfarb S,. Predictive performance of ten equations for estimating creatinine clearance in cardiac patients. Iohexol Cooperative Study Group. Ann Pharmacother 1998; 32: 1275-83.
Pai MP,. Estimating the glomerular filtration rate in obese adult patients for drug dosing. Adv Chronic Kidney Dis 2010; 17: e53-62.
Lim WH, Lim EM, McDonald S,. Lean body mass-adjusted Cockcroft and Gault formula improves the estimation of glomerular filtration rate in subjects with normal-range serum creatinine. Nephrology (Carlton) 2006; 11: 250-6.
Winter MA, Guhr KN, Berg GM,. Impact of various body weights and serum creatinine concentrations on the bias and accuracy of the Cockcroft-Gault equation. Pharmacotherapy 2012; 32: 604-12.
Chew-Harris JSC, Chin PK, Florkowski CM, George P, Endre Z,. Removal of body surface area normalisation improves raw-measured GFR estimation by the CKD-EPI equation and drug dosing in the obese. Intern Med J. 2015 July; 45 (7): 766-73.
Masson I, Maillard N, Delanaye P, Moranne O, Alamartine E, Mariat C,. GFR estimation using standardized cystatin C in kidney transplant recipients. Am J Kidney Dis 2013; 61: 279-84.
Okparavero AA, Tighiouart H, Krishnasami Z, Graham H, Hellinger J, Inker LA,. Use of glomerular filtration rate estimating equations for drug dosing in HIV-positive patients. Antivir Ther 2013; 18: 793-802.
Fotheringham J, Weatherley N, Kawar B, G Fogarty D, Ellam T,. The body composition and excretory burden of lean, obese, and severely obese individuals has implications for the assessment of chronic kidney disease. Kidney Int 2014; 86: 1221-8.
Comerma-Steffensen S, Grann M, Andersen CU, Rungby J, Simonsen U,. Cardiovascular effects of current and future anti-obesity drugs. Curr Vasc Pharmacol 2014; 12: 493-504.
Scheen AJ,. Pharmacokinetic considerations for the treatment of diabetes in patients with chronic kidney disease. Expert Opin Drug Metab Toxicol 2013; 9: 529-50.
Inzucchi SE, Bergenstal RM, Buse JB, Tsapas A, Wender R, Matthews DR,. Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2015; 58: 429-42.
Sketris I, Lesar T, Zaske DE, Cipolle RJ,. Effect of obesity on gentamicin pharmacokinetics. J Clin Pharmacol 1981; 21: 288-93.
Blouin RA, Bauer LA, Miller DD, Record KE, Griffen WO,. Vancomycin pharmacokinetics in normal and morbidly obese subjects. Antimicrob Agents Chemother 1982; 21: 575-80.
Sparreboom A, Wolff AC, Mathijssen RHJ, Rowinsky EK, Verweij J, Baker SD,. Evaluation of alternate size descriptors for dose calculation of anticancer drugs in the obese. J Clin Oncol 2007; 25: 4707-13.
O'Dwyer PJ, Stevenson JP, Johnson SW,. Clinical pharmacokinetics and administration of established platinum drugs. Drugs 2000; 59: 19-27.
Gaspari F, Ruggenenti P, Porrini E, Motterlini N, Cannata A, Carrara F,. The GFR and GFR decline cannot be accurately estimated in type 2 diabetics. Kidney Int 2013; 84: 164-73.
Medeiros FSR, Sapienza MT, Prado ES, Buchpiguel CA, Ianhez LE, David-Neto E,. Validation of plasma clearance of 51Cr-EDTA in adult renal transplant recipients: comparison with inulin renal clearance. Transpl Int 2009; 22: 323-31.
